Organon & Co. · NYSE:OGN

Organon & — Merger or Acquisition (2024)

13 slides from Organon &'s merger presentation, 2024

  1. Slide 1: Organon Strengthens Portfolio and Growth Profile with Structured Acquisition of Dermavant

    Organon Strengthens Portfolio and Growth Profile with Structured Acquisition of Dermavant

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements Except for historical information, this presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements abo

  3. Slide 3: Strengthens Organon Portfolio and Growth Profile with Structured Acquisition of Dermavant

    Strengthens Organon Portfolio and Growth Profile with Structured Acquisition of Dermavant Adds differentiated commercial therapeutic for the treatment of psoriasis and in development for atopic dermatitis - diseases with significant unmet medical need Extends Organon’s international dermatology capa

  4. Slide 4: VTAMA Overview

    VTAMA Overview First-in-class aryl hydrocarbon receptor (AhR) agonist approved in the US in 2022 for plaque psoriasis in adults Differentiated profile versus other topical agents Psoriasis launch progressing; script volume growing at 20+% YoY Positive clinical data supports approximately 4x expansio

  5. Slide 5: VTAMA Represents Meaningful, Durable Commercial Opportunity

    VTAMA Represents Meaningful, Durable Commercial Opportunity Psoriasis Atopic Dermatitis2 • Affects approximately 125 million people • Affects approximately 200 million people worldwide worldwide • Global market sales of ~$24B in 2022 • Global market sales of ~$8.5B in 2022 • Expected to increase at

  6. Slide 6: VTAMA is Differentiated vs. Other Topicals

    VTAMA is Differentiated vs. Other Topicals Favorable Safety and Favorable Clinical Profile Easy to Use Tolerability Profile • Only topical with on label • No limits on duration of use or • Single formulation/dose across “remittive off-treatment effect” location of use as psoriasis and, if approved,

  7. Slide 7: VTAMA Launch Progressing in Psoriasis with Expected Acceleration After Atopic Dermatitis Approval

    VTAMA Launch Progressing in Psoriasis with Expected Acceleration After Atopic Dermatitis Approval Psoriasis Branded Topical Market – Weekly TRx1 Total Weekly TRx2 556k 42k Atopic Dermatitis 385k 344k Systemics Q4 Topicals PDUFA 69k Psoriasis 176k Current Systemics 102k Topicals ~5k Approval VTAMA VT

  8. Slide 8: VTAMA is Well-Positioned to Expand into AD

    VTAMA is Well-Positioned to Expand into AD ADORING 1 and 2 Successful Across All Primary and Secondary Endpoints vIGA-AD EASI-75 PP-NRS 80% ADORING 1 ADORING 2 ADORING 1 ADORING 2 ADORING 1 ADORING 2 70% P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P = 0.0366 P = 0.0015 59% 60% 56% 56% 53% 50% 45% 46

  9. Slide 9: Organon Well-Positioned to Drive Growth

    Organon Well-Positioned to Drive Growth • Global scale and reach in ~140 • US commercial product with countries differentiated profile • Global commercial, regulatory, • Near term expansion opportunity medical affairs and supply chain in atopic dermatitis capabilities • Deep expertise in dermatology

  10. Slide 10: Transaction Overview

    Transaction Overview • Organon has agreed to acquire Dermavant equity for an upfront purchase price of $175 million • Additional potential milestone payments of $75 million for the commercial approval of VTAMA in Transaction atopic dermatitis and up to $950 million for the achievement of certain com

  11. Slide 11: Key Takeaways

    Key Takeaways Dermavant acquisition… ✓ Adds an innovative, differentiated commercial product with significant runway ✓ Immediately contributes to Organon’s revenue growth and enhances long-term growth profile ✓ Extends Organon’s international dermatology capabilities to the US ✓ Benefits from Organo

  12. Slide 12: Appendix

    Appendix © “i ORGANON » Hote forherheatth

  13. Slide 13: Acronyms

    Acronyms AD – Atopic dermatitis BID – Two times a day CAGR – Compound annual growth rate EASI-75 – 75% reduction from baseline in Eczema Area and Severity Index EBITDA – Earnings before interest, taxes, depreciation, and amortization GAAP – Generally accepted accounting principles HCP – Health care

Organon & — Merger or Acquisition (2024) on 6ix